-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Revolution Medicines, Inc. (NASDAQ:RVMD) Insider Xiaolin Wang Sells 735 Shares
Revolution Medicines, Inc. (NASDAQ:RVMD) Insider Xiaolin Wang Sells 735 Shares
Revolution Medicines, Inc. (NASDAQ:RVMD – Get Rating) insider Xiaolin Wang sold 735 shares of the company's stock in a transaction on Monday, September 19th. The shares were sold at an average price of $19.04, for a total value of $13,994.40. Following the sale, the insider now directly owns 31,235 shares of the company's stock, valued at $594,714.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Revolution Medicines Stock Down 10.5 %
Shares of RVMD traded down $2.04 during midday trading on Wednesday, reaching $17.48. 650,345 shares of the stock were exchanged, compared to its average volume of 767,638. Revolution Medicines, Inc. has a 12-month low of $14.08 and a 12-month high of $34.16. The firm has a 50 day simple moving average of $22.32 and a 200-day simple moving average of $20.95. The company has a market cap of $1.53 billion, a price-to-earnings ratio of -5.98 and a beta of 1.68.
Get Revolution Medicines alerts:Revolution Medicines (NASDAQ:RVMD – Get Rating) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.82) EPS for the quarter, beating analysts' consensus estimates of ($0.87) by $0.05. The business had revenue of $9.12 million for the quarter, compared to analyst estimates of $8.75 million. Revolution Medicines had a negative return on equity of 39.20% and a negative net margin of 823.65%. Research analysts expect that Revolution Medicines, Inc. will post -3.33 earnings per share for the current fiscal year.
Institutional Trading of Revolution Medicines
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RVMD. Point72 Hong Kong Ltd acquired a new stake in Revolution Medicines in the 2nd quarter valued at approximately $39,000. Nisa Investment Advisors LLC grew its holdings in Revolution Medicines by 53.6% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,150 shares of the company's stock valued at $42,000 after buying an additional 750 shares during the last quarter. Goodman Advisory Group LLC acquired a new stake in Revolution Medicines in the 2nd quarter valued at approximately $54,000. Amundi acquired a new stake in Revolution Medicines in the 2nd quarter valued at approximately $131,000. Finally, Virtus ETF Advisers LLC grew its holdings in Revolution Medicines by 9.7% in the 4th quarter. Virtus ETF Advisers LLC now owns 6,746 shares of the company's stock valued at $170,000 after buying an additional 596 shares during the last quarter. Institutional investors and hedge funds own 86.70% of the company's stock.Analysts Set New Price Targets
Several equities research analysts have recently commented on the company. SVB Leerink reduced their target price on Revolution Medicines from $31.00 to $30.00 and set an "outperform" rating for the company in a report on Wednesday, August 10th. HC Wainwright reduced their target price on Revolution Medicines from $40.00 to $37.00 and set a "buy" rating for the company in a report on Wednesday, August 17th.
About Revolution Medicines
(Get Rating)
Revolution Medicines, Inc, a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors.
Further Reading
- Get a free copy of the StockNews.com research report on Revolution Medicines (RVMD)
- General Mills: Superior Returns With Less Volatility
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
Revolution Medicines, Inc. (NASDAQ:RVMD – Get Rating) insider Xiaolin Wang sold 735 shares of the company's stock in a transaction on Monday, September 19th. The shares were sold at an average price of $19.04, for a total value of $13,994.40. Following the sale, the insider now directly owns 31,235 shares of the company's stock, valued at $594,714.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
革命医药公司(纳斯达克代码:RVMD-GET Rating)内部人士王晓林在9月19日星期一的一笔交易中出售了735股该公司股票。这些股票的平均价格为19.04美元,总价值为13,994.40美元。出售后,这位内部人士现在直接持有该公司31,235股股票,价值594,714.40美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可以通过此超链接.
Revolution Medicines Stock Down 10.5 %
革命医药公司股价下跌10.5%
Shares of RVMD traded down $2.04 during midday trading on Wednesday, reaching $17.48. 650,345 shares of the stock were exchanged, compared to its average volume of 767,638. Revolution Medicines, Inc. has a 12-month low of $14.08 and a 12-month high of $34.16. The firm has a 50 day simple moving average of $22.32 and a 200-day simple moving average of $20.95. The company has a market cap of $1.53 billion, a price-to-earnings ratio of -5.98 and a beta of 1.68.
周三午盘交易中,RVMD的股价下跌2.04美元,至17.48美元。该股成交量为650,345股,而平均成交量为767,638股。Revine Medicines,Inc.的12个月低点为14.08美元,12个月高位为34.16美元。该公司的50日简单移动均线切入位为22.32美元,200日简单移动均线切入位为20.95美元。该公司市值15.3亿美元,市盈率为-5.98倍,贝塔系数为1.68。
Revolution Medicines (NASDAQ:RVMD – Get Rating) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.82) EPS for the quarter, beating analysts' consensus estimates of ($0.87) by $0.05. The business had revenue of $9.12 million for the quarter, compared to analyst estimates of $8.75 million. Revolution Medicines had a negative return on equity of 39.20% and a negative net margin of 823.65%. Research analysts expect that Revolution Medicines, Inc. will post -3.33 earnings per share for the current fiscal year.
革命医药公司(纳斯达克代码:RVMD-GET Rating)最近一次发布季度收益数据是在8月9日星期二。该公司公布了该季度每股收益(0.82美元),比分析师普遍预期的(0.87美元)高出0.05美元。该业务本季度营收为912万美元,而分析师预期为875万美元。革命医药公司的净资产回报率为负39.20%,净利润率为负823.65%。研究分析师预计,Revine Medicines,Inc.将公布本财年每股收益为3.33美元。
Institutional Trading of Revolution Medicines
革命药品的制度性交易
Analysts Set New Price Targets
分析师设定新的价格目标
Several equities research analysts have recently commented on the company. SVB Leerink reduced their target price on Revolution Medicines from $31.00 to $30.00 and set an "outperform" rating for the company in a report on Wednesday, August 10th. HC Wainwright reduced their target price on Revolution Medicines from $40.00 to $37.00 and set a "buy" rating for the company in a report on Wednesday, August 17th.
几位股票研究分析师最近对该公司发表了评论。SVB Leerink在8月10日(周三)的一份报告中将Revine Medicines的目标价从31.00美元下调至30.00美元,并为该公司设定了“跑赢大盘”的评级。在8月17日周三的一份报告中,HC Wainwright将Revine Medicines的目标价从40.00美元下调至37.00美元,并为该公司设定了“买入”评级。
About Revolution Medicines
关于革命医药
(Get Rating)
(获取评级)
Revolution Medicines, Inc, a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors.
革命药物公司是一家临床阶段的精确肿瘤学公司,专注于开发治疗方法,以抑制RAS成瘾癌症的前沿靶点。该公司正在开发SHP2的抑制剂RMC-4630,该药处于1/2期临床试验,用于治疗实体肿瘤,如妇科和结直肠癌肿瘤。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Revolution Medicines (RVMD)
- General Mills: Superior Returns With Less Volatility
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- 免费获取StockNews.com关于革命药物的研究报告(RVMD)
- 通用磨坊:波动性更小、回报更高
- 连续60年提高股息的3只防御性股票
- 3家航空公司股票陷入持有格局
- Roku股票下跌,但并未出局
- 如果你渴望价值,那就尝尝露丝的好客之道吧
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
接受《革命医药日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对革命药物和相关公司的评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧